Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Diagnostic Radiologists :Nuclear Radiology

Articles with lock require a subscription to GLG News | Request a free trial
August 29, 2008
This is bad news for Cell Genesys but may use for other treatment
Analysis of: Cell Genesys Ends Clinical Trials For Prostate Cancer Treatment | online.wsj.com
Author: GLG Expert Contributor
 1. Radioimmunoassay is very hard to  proof the basic biology of metastatic patient. 2.  GVAX  Immunotherapy is basically modify the  GM-CSF, so the exact biology of immune system of the patient  should be considered in metastatic stage before use. As the tumor is already...
August 26, 2008
Temozolomide and Thalidomide combination therapy for Malignant Melanoma
Analysis of: Temozolomide And Thalidomide Combination Effective Against Malignant Melanoma Spread To CNS And White Blood Cell Count May Be Prognostic | www.medicalnewstoday.com
Author: GLG Expert Contributor
1.  The phase II clinical trial  of the combination thherapy of ( temozolomide and Thalidomide for Malignant Melanoma is very encourganing. It may open new avenue to treat   malignant melanoma  affecting Brain. 2. This  article is important for use  of combination...
August 22, 2008
The FInal Cervical cancer Vaccine is media hype
Analysis of: Drug Makers’ Push Leads to Cancer Vaccines’ Fast Rise | www.nytimes.com
Author: GLG Expert Contributor
1.  Merck and GSK are pushing too much for Cerival cancer vaccine advertisement. 2.  Merck ( Gardasil), and GSK( cervarix) are very tiny age applications, but real disease start after 20, so early vaccination is no use, but Pap smear is more helpful 3. So drug marker push to cancer vaccine lead...
August 21, 2008
There is a hope for NHL ( Non-Hodgkin's Lymphoma).
Analysis of: Biovest Reports Results for Patients Treated with Anti-Cancer Vaccine: BiovaxID(R) Demonstrates Clinically and Statistically Significant Improvement of Disease-Free Survival in Non-Hodgkin's Lymphoma in Pivotal Phase 3 Clinical Trial | biz.yahoo.com
Author: GLG Expert Contributor
1. BiovaxID®  is a personalized, patient-specific therapeutic vaccine designed to stimulate the patient's own immune system to recognize and destroy cancerous B-cells that may remain in the body or may arise after the patient has been treated with chemotherapy. 2. Unlike many other approaches...
August 19, 2008
Byetta sale will reduce after FAD alert
Analysis of: FDA Alert: Hemorrhagic or Necrotizing Pancreatitis in Patients Taking Byetta | www.fda.gov
Author: GLG Expert Contributor
 1. As Byetta is not monotherapy and the clinical trial results  are  not clear about the condition od trial patient, so future of Byetta is  blink
August 14, 2008
Imaging and therapeutic agents for Brain tumor ( glioblastoma multiforme)
Analysis of: Recent Popular New Reports About Senator Ted Kennedy's Brain Tumor | www.cnn.com
Author: GLG Expert Contributor
1.  Public awareness and budget for research for brain will increase. 2. Federal      funding  should increase for GBM ( Glioblastoma multiforme) 3. More researchers will join in this field
August 13, 2008
First serum ELISA for hepcidin
Analysis of: UCLA And Biotech Company Develop First Blood Test To Measure Key Hormone That Regulates Iron | www.medicalnewstoday.com
Author: GLG Expert Contributor
 Hepcidin the principal iron-regulatory hormone that has been very difficult to measure but earlier it was measured indirect way ( basically   measure the iron binding protein transferrin and ferritin). To overcome this difficulty UCLA group developed new procedure to  measure...
August 11, 2008
Byetta sale will remain assuch or decrease
Analysis of: Lilly Diabetes Drug Shows a Life-Extending Promise | www.nytimes.com
Author: GLG Expert Contributor
1. The efficacy is not not know about life exdending ( may be the results are coming from heakthy person), so it is not clear. 2. Patient taking injection 2 times is not feasible for long run basis. 3. It  is not monotherapy.
August 8, 2008
Federal Govt. Should be the cost
Analysis of: UK Says Kidney Cancer Drugs Are Too Pricey | www.pharmalot.com
Author: GLG Expert Contributor
1. Kidney cancer drugs have the potential to extend progression-free survival by five to six months, but at a cost of $40,000 to $70,000 per patient per year.  2. The cost per quality adjusted life year (QALY) gained of these treatments is between $57,000 and $180,000 per patient - based on...
August 7, 2008
FDA will ask for more data
Analysis of: AstraZeneca and Bristol-Myers Squibb Submit New Drug Application in the United States and Marketing Authorisation Application in Europe for ONGLYZA™ (Saxagliptin) for the Treatment of Type 2 Diabetes | www.astrazeneca.com
Author: GLG Expert Contributor
Saxagliptin is being studied in clinical trials as a once-daily therapy to determine its efficacy and safety. Saxagliptin was specifically designed to be a selective, reversible inhibitor of the DPP-4 enzyme, with dual routes of clearance. Phase III data for saxagliptin have previously been presented...

Page : 1 2 Next1 to 10 of 19

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-08-30T01:45:15.453